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Abstract
Large scale gene expression (transcriptome) analysis and genome-wide association studies (GWAS) for single nucleotide
polymorphisms have generated a considerable amount of gene- and disease-related information, but heterogeneity and
various sources of noise have limited the discovery of disease mechanisms. As systematic dataset integration is becoming
essential, we developed methods and performed meta-clustering of gene coexpression links in 11 transcriptome studies
from postmortem brains of human subjects with major depressive disorder (MDD) and non-psychiatric control subjects. We
next sought enrichment in the top 50 meta-analyzed coexpression modules for genes otherwise identified by GWAS for
various sets of disorders. One coexpression module of 88 genes was consistently and significantly associated with GWAS for
MDD, other neuropsychiatric disorders and brain functions, and for medical illnesses with elevated clinical risk of depression,
but not for other diseases. In support of the superior discriminative power of this novel approach, we observed no
significant enrichment for GWAS-related genes in coexpression modules extracted from single studies or in meta-modules
using gene expression data from non-psychiatric control subjects. Genes in the identified module encode proteins
implicated in neuronal signaling and structure, including glutamate metabotropic receptors (GRM1, GRM7), GABA receptors
(GABRA2, GABRA4), and neurotrophic and development-related proteins [BDNF, reelin (RELN), Ephrin receptors (EPHA3,
EPHA5)]. These results are consistent with the current understanding of molecular mechanisms of MDD and provide a set of
putative interacting molecular partners, potentially reflecting components of a functional module across cells and biological
pathways that are synchronously recruited in MDD, other brain disorders and MDD-related illnesses. Collectively, this study
demonstrates the importance of integrating transcriptome data, gene coexpression modules and GWAS results for
providing novel and complementary approaches to investigate the molecular pathology of MDD and other complex brain
disorders.
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Introduction
Major depressive disorder (MDD) is a common psychiatric
disease with an estimated prevalence of 5.3% for a 12- month
period and 13.2% for a lifetime disorder [1], a high rate of
recurrence [2], a higher prevalence in women [3], and a
heritability of 37% (95% CI=31%–42%) [4]. Transcriptome
(the set of all expressed genes in a tissue sample) and genome-wide
association studies (GWAS) have separately provided clues to
mechanisms of MDD, although not to the anticipated extent.
Transcriptome studies mostly focus on changes in gene expression
in disease states (altered expression), but also provide unique
opportunities for assessing the less-investigated changes in the
coordinated function of multiple genes (altered coexpression) [5].
GWAS seek to identify genetic markers for diseases, and have
generated some findings in MDD [6,7,8,9,10], but overall results
from GWAS meta-analyses have been disappointing [11,12],
potentially due to the complexity of the disease and heterogeneity
of patient cohorts. GWAS and transcriptome studies are highly
complementary in that they provide unbiased and large scale
investigation of DNA structural [single nucleotide polymorphisms
(SNP) and other variants] and functional (RNA expression)
changes across conditions, although these two approaches are
only beginning to be integrated [13,14,15,16,17].
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Gene arrays allow for the unbiased quantification of expression
(mRNA transcript levels) for 10,000 to 20,000 genes simulta-
neously. Since gene transcript levels represent the integrated
output of many regulatory pathways, the study of all expressed
genes provides an indirect snapshot of cellular function under
diverse conditions. For instance, using postmortem brain samples,
this approach has implicated dysregulated BDNF, GABA,
glutamate and oligodendrocyte functions in MDD
[18,19,20,21,22]. However, current studies are still few, were
performed in heterogeneous cohorts, and utilized early and
rudimentary versions of gene arrays. Moreover, gene array studies
are subject to similar limitations as early GWA studies, in that
large number of genes are tested in few subjects (n = 10–100).
Typical analyses identify 1–10% of genes affected in the illness
(differentially expressed genes), are characterized by high rates of
false discovery, and may be confounded by numerous clinical
(drug exposure, subtypes, duration, etc.), demographic (age, sex,
race), technical parameters (RNA integrity, brain pH, postmortem
interval for brain collection), or other potential co-segregating
factors of unknown origin (See [13] for discussion). Conditions of
postmortem brain collection also preclude the reliable identifica-
tion of acute state-dependent gene changes, but are appropriate
for investigating stable long-term disease-related homeostatic
adaptations.
Gene coexpression studies offer complementary perspectives on
gene changes in the context of transcriptome studies. Here, two
genes are defined as coexpressed in a dataset if their patterns of
expression are correlated across samples. Coexpression reflects
possible shared function between genes, and may arise through
multiple biological pathways including cellular coexpression and
common regulatory pathways (e.g., hormone signaling, transcrip-
tion factors) [23,24]. Hence, coexpression links have been used to
build gene networks, and to identify communities, or modules, of
genes with shared functions [25,26]. Notably, by incorporating
multiple interactions among a large number of genes, the study of
gene coexpression networks provides an approach to tackle the
complexity of biological changes occurring in complex polygenic
disorders [24]. See [5] for a general review.
Concepts and methods for integrating functional (transcrip-
tome) and structural (DNA polymorphism GWA) studies of the
molecular bases of complex neuropsychiatric disorders such as
MDD need to be developed to harness the potential of systematic
large-scale molecular and genetic investigations of the brain. Here,
our central hypothesis states that stable brain co-regulation
modules identified through meta-analysis of multiple transcrip-
tome studies may overlap with sets of genes and associated SNPs
related to MDD. Based on the continuum of pathological changes
between MDD and other brain disorders [27] and co-morbidity
with selected medical illnesses including cardiovascular diseases
and metabolic syndrome [28,29], we also predicted that MDD
coexpression modules may be enriched in genes identified by
GWAS for other psychiatric and brain disorders and potentially
for medical illnesses related to depression, together identifying
functionally-coherent gene sets implicated in MDD-related disease
processes.
Materials and Methods
Figure 1 illustrates the meta-clustering and validation methods
of the approach. In step I, we identified 50 robust co-regulation
modules in human brains by combining 11 transcriptome datasets
collected from several brain regions in different cohorts of subjects
with MDD and non-affected comparison subjects. Steps II and III
were performed to identify MDD-related gene modules, and
exclude other gene modules linked to biological functions not
related to MDD. In step II, we collected different sets of genes
located nearby SNPs identified by GWAS for MDD, neuropsy-
chiatric disorders, related traits, and for systemic diseases often
associated with psychiatric disorders, and performed gene set
analysis to identify MDD-related gene modules. In step III, we
performed functional annotations of gene module members by
using 2,334 gene sets collected from MSigDB (http://www.
broadinstitute.org/gsea/msigdb/). We also organized genes iden-
tified by SNPs in published GWAS into three categories (cancer
studies, human body indices and unrelated diseases) and treated
them as a non-MDD-related negative control gene sets in step IV.
Transcriptome Data Sets
Eleven MDD microarray datasets generated in our lab were
used here. Cohorts and brain areas investigated are listed in
Table 1 and details were provided in [30,31]. Among these
studies, six used Affymetrix Human Genome U133 Plus 2.0
platforms (Affymetrix Inc., Santa Clara, CA), two used Affymetrix
Human Genome U133A platforms, and the remaining three used
Human HT-12 arrays from Illumina (Illumina Inc, San Diego,
CA). Figure S1 provides a diagram and results of the
transcriptome dataset preprocessing procedures. Data has been
deposited to the NCBI Geo database with accession numbers:
GSE54562, GSE54563, GSE54564, GSE54565, GSE54566,
GSE54567, GSE54568, GSE54570, GSE54571, GSE54572 and
GSE54575.
For gene matching across studies, when multiple probes or
probe sets match to one gene symbol, we choose the probe set with
the largest variation (largest interquartile range; IQR) to represent
the gene [32]. See below and Figure S3 for probe overlap
assessment. For preprocessing, data were log-transformed (base 2).
Non-expressed (small mean intensity) and non-informative (small
standard deviation) genes were filtered out. To perform such
filtering for 11 studies simultaneously, we calculated the ranks of
row means and row standard deviations of each gene in each
single study. The ranks were summed up across 11 studies and
used as criteria to filter out non-expressed and non-informative
genes. Note that ideally we should map the probes across
platforms to large overlapped locations so we make sure they
measure the same signal. There are, however, several reasons that
doing so may not be possible or optimal. First, Affymetrix
probesets are designed with combination of multiple short probes
and Illumina arrays use a single and longer probe. As a result,
Affymetrix probes have large ‘‘target regions’’ (044–728 KB, 95%
coverage of the 88 genes of module #35 we investigated in Figure
S3) which are covered by multiple short probes, while Illumina’s
probe is only around 50 bp. Secondly, many other factors affect
signal detection efficiency, including exact probe sequence,
integration of multiple probeset in Affymetrix arrays, hybridization
efficiency, GC content, cross hybridization, etc. As a whole these
differences can affect the consistency of the results and potentially
decrease the final signal. For the purpose of running the meta-
analysis (as opposed to single study analysis) it has been
recommended to use the probe set with the largest IQR to
represent a gene symbol [32]. We want to point out that if the
IQR probe matching procedure had introduced large errors, the
meta-analyzed modules would not have been detected by chance.
Meta-clustering of Transcriptomic Data to Construct Co-
expression Gene Modules
The 11 transcriptome studies were combined to construct co-
expression gene modules using a meta-clustering technique
described below. We denoted by Xgsk the gene expression intensity
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Figure 1. Overall analytical strategy. In step I, 50 co-regulation modules were generated using meta-clustering of gene clusters identified by the
‘‘penalized K-medoids’’ method across 11 transcriptome MDD and matched controls studies. In step II, modules enriched from most of the selected
GWAS studies related to MDD, neuropsychiatric disorder and traits, including systemic disease linked to psychiatric disorders were identified. In step
III, the biological functions represented by genes included in each module were defined by pathway analysis from 2,334 gene sets of MSigDB (www.
broadinstitute.org/gsea/msigdb). In step IV, SNPs from the Catalog of GWAS were organized into three categories: cancer GWAS, human body indices
GWAS and GWAS for common diseases and medial illnesses unrelated to MDD or other brain function. Three additional categories were defined as
non-MDD-related negative control gene sets. (Note: In order to increase the performance of the heatmap in module #35, we first performed the
hierarchical clustering with ‘‘complete’’ agglomeration method to aggregated samples with similar expression among all 88 genes, and the genes
were sorted by the correlation from high to low of selected genes in the top.).
doi:10.1371/journal.pone.0090980.g001
Table 1. Description of cohorts in 11 MDD microarray platforms.
Cohort Region Code Platform # of probe sets # of genes # of subjects
1 ACC MD1_ACC Affymetrix Human Genome U133 Plus 2.0 40,610 19,466 32
2 AMY MD1_AMY Affymetrix Human Genome U133 Plus 2.0 40,610 19,621 28
3 ACC MD2_ACC Illumina HumanHT –12 (v3) 48,803 25,159 20
4 ACC MD3_ACC Illumina HumanHT –12 (v3) 48,803 25,159 50
5 AMY MD3_AMY Illumina HumanHT –12 (v3) 48,803 25,159 42
6 ACC BA25_F Affymetrix Human Genome U133 Plus 2.0 53,596 19,572 26
7 ACC BA25_M Affymetrix Human Genome U133 Plus 2.0 53,596 19,572 26
8 DLPFC BA9_F Affymetrix Human Genome U133 Plus 2.0 53,596 19,572 32
9 DLPFC BA9_M Affymetrix Human Genome U133 Plus 2.0 53,596 19,572 28
10 OFC NY_BA47 Affymetrix Human Genome U133A 20,338 12,703 24
11 DLPFC NY_BA9 Affymetrix Human Genome U133A 20,338 12,703 26
ACC, anterior cingulate cortex; AMY, amygdala; DLPFC, dorsolateral prefrontal cortex, OFC, orbital ventral prefrontal cortex.
doi:10.1371/journal.pone.0090980.t001
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of gene g, sample s and study k, and Xgk= (Xg1k,…, XgSk) the vector
of gene expression intensities of gene g and study k. We defined the
dissimilarity measure between gene i and gene j for a given study k
as d
(k)
i,j ~ 1{Dcor Xik,Xjk
 
D, where cor(Xik, Xjk) is the Pearson
correlation of the two gene vectors. To combine the dissimilarity
information of the K= 11 studies, we took the mean of meta-







ij ). Given the meta-dissimilarity
measure, the ‘‘Penalized K-medoids’’ clustering algorithm was
then applied to construct co-expression gene modules [33]. The








where the clustering result C~(C1,    ,CH ,S) contains H non-
overlapping gene clusters (i.e. H gene modules C1,    ,CH ) and a
set of scattered genes S that cannot be clustered into any of the
tight gene modules, gh denotes the medoid gene of cluster h such
that its average dissimilarity to all other genes in the cluster is
minimal, DSD is the size of the scattered gene set S and l is a tuning
parameter controlling tightness of detected gene modules and the
number of scattered genes discarded to S. The first term of the
target function L(C) calculates the total sum of within-cluster
dispersion and is essentially the K-medoids algorithm (an extended
form of K-means using arbitrary non-Euclidean dissimilarity
measure). The second penalty term allows scattered genes not to
be clustered into any gene module. For example, if the distances of
a gene gi to all cluster medoids are greater than l, minimizing L(C)
will assign the gene into the scattered gene set S, instead of into any
gene cluster. Intuitively, smaller l generates tighter clusters and
allow more genes into scattered gene set S. The rationale for the
choice of this approach was based on finding in the literature,
where comparative studies show that many genes are not tightly
co-expressed with any gene clusters and methods that allow
scattered gene assignment generates tighter gene modules that are
biologically more informative [34].
Parameter Selection and Evaluation of Meta-clustering
We tested different parameter settings of H=50 or 100
modules, and l such that b=0%, 25% or 50% of genes are left
to scattered gene set S. In all performance of the 263= 6
combinations for the meta-clustering method, a biological
validation was performed using biological pathway information.
We searched ten keywords (‘‘GABA’’, ‘‘Insulin’’, ‘‘Diabetes’’,
‘‘Immune’’, ‘‘Thyroid’’, ‘‘Estrogen’’, ‘‘Depression’’, ‘‘Alzheimer’’,
‘‘Parkinson’’ and ‘‘Huntington’’) in MSigDB and finally obtained
98 MDD-related pathways. In each clustering result, Fisher’s exact
test was applied to each module to correlate with each of the 98
MDD-related pathways and eight GWAS gene lists and the p-
values were generated. Wilcoxon signed rank test was used to
compare any pair of clustering results (from different parameter
setting) so that the best parameter setting could be determined.
Evaluation of Robustness and Stability of Meta-clustering
Method
To evaluate the robustness of the meta-clustering results, we
used the Adjusted Rand Index (ARI) as a measurement of
consistency between two clustering results [35]. Specifically, ARI
calculates the proportion of concordant gene pairs across two
clustering results (i.e. two genes are clustered together in both
clustering results or not clustered together in both) among all
possible gene pairs and the index is standardized between 0 and 1,
where 0 reflects expected similarity measure of two random
clustering and 1 reflects similarity measure between two identical
clustering. We randomly selected a subset of studies (n = 8, 9 or 10)
from 11 MDD studies and calculated the ARI to assess the
similarity of the obtained modules compared to those obtained
using the 11 MDD studies. The procedure was repeated 100 times
and the average ARI was calculated. For the stability of meta-
clustering method, the mean and standard deviation of ARIs were
obtained by bootstrapping method [36] (sampled with replace-
ment to obtain the same number of samples for each single study),
where the 11 MDD studies were bootstrapped 100 times.
Genome-wide Association Studies (GWAS)-related Gene
Categories
Eight neuropsychiatry-related candidate gene lists and three
gene lists from presumably unrelated disorders or traits were
identified from relevant GWAS. Individual genes were identified
by the presence of GWAS significant SNPs within a given
nucleotide distance from the coding region of that gene (UCSC
hg18 with build 36.3 was used for all GWAS).
– The first gene list was obtained from a published GWAS for
neuroticism [37]. Neuroticism is a personality trait that reflects
a tendency toward negative mood states, and that is linked to
several internalizing psychiatric conditions. That GWAS
involved 1,227 healthy individuals with self-report of no
diagnosis or treatment for schizophrenia, schizoaffective
disorder or bipolar disorder and personality measures of
neuroticism. Genotyped data were generated from Affymetrix
GeneChip Human Mapping 500 K using BRLMM algorithm.
449 SNPs were selected by p-value less than 0.001, and 155
genes were identified to have contained one or more selected
SNPs in the 10 kilobases (kb) up- and down-stream extension of
the coding regions.
– The second gene list was obtained from the MDD 2000+
project that included a meta-analysis of MDD studies with
2,431 MDD cases and 3,673 controls [38]. Similarly, 532 SNPs
with p-value less than 0.001 were mapped to gene coding
regions (including 10 kb upstream and downstream regions)
and 159 genes were identified.
– The third gene list was obtained from a mega-analysis of
GWAS for MDD [11]. The associated 202 SNPs’ p-values
were less than 1025 and 52 genes were identified using the
University of California Santa Cruz Human Genome Browser,
hg18 assembly (UCSC hg18) with build 36.3. Gene symbols
from the build version 36.3 in the National Center for
Biotechnology Information (NCBI) database were used.
– The fourth candidate gene list was obtained from a mega-
GWAS of bipolar disease which contained 7,481 patients and
9,250 controls [39]. 6,887 SNPs were identified when p-value
less than 0.001. By mapping the SNPs to gene coding region
using SNPnexus software (http://snp-nexus.org/), 602 genes
were obtained.
– For the fifth to eighth gene lists, we interrogated the Catalog of
Published Genome-Wide Association Studies [40] (http://
www.genome.gov/gwastudies/). The database (as of 01/31/
13; time of the latest data analysis update) contained 10,183
entries of disease- or trait-associated SNPs with p-values
smaller than 1025 in 1,491 GWAS studies. We manually
regrouped the disorders and traits into 4 categories: (1) all
MDD-related studies, (2) all neuropsychiatric disorder studies,
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(3) all neurological disorder and brain phenotypes studies, (4)
all medical illnesses sharing increased risk with MDD. Note
that the genes in the list #3 were included in the list #2, and
genes in the list #2 were included in the list #1, which is the
larger category (see more detail list in Table S1). Lists #4 is
independent and non-overlapping with others. The associated
four gene lists were then compiled, and genes were uniquely
included when the mapped SNP was within the gene region
including a 100 kb upstream and downstream.
– As negative controls, we identified in the catalog of published
GWAS three gene sets presumably not related to psychiatric
diseases: (a) 65 publications (270 genes) of cancer GWAS
studies; (b) 42 publications (459 genes) of human body indices
GWAS studies (HBI: genetic phenotypes for human, for
example: height, weight, eye color, etc.); and (c) 33 publications
(187 genes) of GWAS studies for common disease traits not
related to brain function or major mental illnesses (Table S2).
Meta-analysis to Aggregate Evidence of Association of
each Module with the GWAS Gene Lists
We performed Fisher’s exact test to examine the significance of
the association of genes within each coexpression module with
individual GWAS-derived gene lists, using the 10,000 genes
evaluated in transcriptome meta-analysis (Figure S1) as back-
ground. To assess statistical significance of association of each
identified module from meta-clustering method, we applied the
Stouffer’s method to combine the p-values obtained from Fisher’s
exact test of the association between gene modules and eight






where w is the cumulative distribution function of a standard
normal distribution [41]. The p-values were assessed for each of
the 50 modules from non-parametric permutation analysis by
randomly selecting the same number of genes from the whole
genome without replacement (using genome background 10,000
genes) for each of the 50 modules and the analysis is repeated for
500 times.
Pathway Analysis and Enrichment Analysis of GWAS
Gene Lists
For biological association, 2,334 annotated pathways (gene sets)
were obtained from MSigDB (www.broadinstitute.org/gsea/
msigdb/), which consists of 880 canonical pathways (217 Biocarta
gene sets, 180 KEGG gene sets, 430 Reactome gene sets and 53
other gene sets) and 1,454 pathways from Gene Ontology (GO).
For each of the gene module, gene set (pathway) analysis was
performed for the 2,334 pathways and 11 GWAS gene lists
(including 3 negative controls). Fisher’s exact test was performed to
assess the biological association between gene modules and given
gene sets. To account for multiple comparisons, Benjamini and
Hochberg procedure was used to control the false discovery rate
(FDR) [42].
Results
Data Preprocessing and Parameter Determination
16,443 genes were retained after gene matching across the 11
studies. Cohorts 10 and 11 were from older platforms with fewer
probesets representing only 12,703 genes (Figure S1). In order to
minimize the loss of information from gene matching, we allowed
20% missing values during matching, i.e., we kept genes with at
least 9 existing measurements out of 11 studies. 13,500 genes were
retained after filtering out lower sum rankings of median row
means, and 10,000 genes after further filtering out lower sum
rankings of median row standard deviations. We then tested
different parameter settings for the number of modules (H=50 or
100), and genes (tuned the l values for controlling tightness of
detected gene modules and the number of scattered genes set) for
b=0%, 25% or 50% of genes left out of the gene set S. In all tests
of the Penalized K-medoids meta-clustering method (263= 6
combinations), we performed a validation by biological pathway
information content. For all clustering results, Fisher’s exact test
was applied to each module to correlate with each of the 98 MDD
pathways and eight GWAS gene lists described in the methods,
and p-values were generated. The Wilcoxon signed rank test was
used to compare any pair of clustering results (from different
parameter settings) so that the best parameter setting could be
determined. The result shows that there was no significant
difference (by Wilcoxon signed rank test) between H=50 and
H=100 clusters except b=0% (i.e., keep all genes), and the
minimum p-value of gene set analysis in H=50 was always lower
than that in H=100 in b=25% and b=50%. It is reasonable to
set the noise level in clustering method because noise will increase
if we combined more studies. We chose H=50 because the mean
of the –log10(p) in 50 modules (3.2793) was higher than 100
modules (3.0224) in b=25%, and the mean of the –log10(p) in 50
modules (3.1896) was higher than 100 modules (3.0588) in
b=50%. 50 modules also provide adequate number and sizes of
gene modules for the purpose of further analyses. Given H=50,
we compared the performance with different choices of b.
b=25% performed better than b=0% (p= 0.0004 using
Wilcoxon signed rank test), and there was no significant difference
between b=25% and b=50% (p= 0.0856). Finally, we selected
H=50 and tuning parameter l such that b=25% genes are left to
scattered gene set S throughout this paper (Table S3).
Construction of 50 Meta-modules from 11 MDD Studies
Using the parameters determined above, we performed a meta-
analysis of module gene membership to identify the top 50 meta-
analyzed coexpression modules across 11 MDD transcriptome
studies. A total of 10,000 genes were clustered using the Penalized
K-Medoid method. 7,797 genes were clustered into K=50
modules and 2,203 genes (b=,25%) were determined as
scattered genes with no coherent expression pattern. We
performed subsampling and bootstrap methods to assess the
stability of the resulting clusters. Subsets (n = 8, 9 or 10) of the 11
studies were randomly selected and the meta-clustering procedure
was similarly applied. The resulting meta-modules were compared
with the meta-modules obtained using the 11 MDD studies using
adjusted Rand index (ARI= 0.47, 0.52 and 0.63 for n = 8, 9, 10).
We also generated bootstrapped samples in each study and
repeated the meta-clustering procedures. Comparison of meta-
modules generated from bootstrapped samples with original
samples generated an average ARI= 0.45 (standard deviation
0.025) in 100 repeated bootstrapping simulations. In the literature,
an ARI of ,0.5 is interpreted as reproducible clustering result
[34], hence demonstrating good stability under data perturbation
(subsampling and bootstrapping) for the 50 meta-modules
obtained by combining 11 studies.
Association of Meta-modules with Eleven GWAS-
determined Gene Lists
We examined association of the 50 meta-modules with the eight
GWAS gene lists using Fisher’s exact test. The results are shown in
Table S4. Module #35 is found to have significant associations
(p,0.05) with the six psychiatric disorder related GWAS gene sets
(p = 0.03 for the neuroticism GWAS gene set; p = 0.03 for MDD
A BDNF/GABA/Glutamate Gene Meta-Module in Depression
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e90980
2000+ project; p = 0.0001 for Mega-GWAS MDD; p=0.03 for
Mega-GWAS of bipolar disorder; p = 0.008 for the catalog of
GWAS studies of neuropsychiatric disorder; p = 0.03 for the
catalog of GWAS studies of neurological disorders and brain
phenotypes) and two studies with borderline p-values (p = 0.05 for
the catalog of MDD-related GWAS studies; p = 0.05 for the
catalog of GWAS studies of Medical illnesses sharing clinical risk
with MDD). We combined the p-values of the eight psychiatric
disorder related GWAS gene sets by Stouffer meta-analysis
method. The p-value of module #35 is 4e205 after the
permutation test (25,000 resamples). In contrast, there was no
association with cancer (p = 1.00), human body indices (p = 0.18)
and other control diseases (p = 0.46) GWAS gene sets. Figure 2
(a) shows the heatmaps of log-transformed p-values from
enrichment analysis for the 50 modules obtained from MDD
cases and controls combined analysis. It shows that module #35
(highlighted in green) from the combined cases and controls
analysis is enriched in genes contained in six MDD-related GWAS
gene sets, but not enriched in the three negative control GWAS
gene sets. None of the other 49 modules showed such consistent
pattern.
During the review process, a new GWAS meta-analysis for
schizophrenia was published by the Psychiatric Genomics
Consortium (PGC) using 1,000 genome Project imputation [43].
Accordingly, we independently examined the reported 52,509
SNPs spanning 2,507 genes under the p-value threshold of 1023
(Table S9). Module #35 was significantly enriched in genes
associated with this new study (p= 0.0013).
Pathway Analysis of Meta-module #35
Table S6 lists detailed information of the 88 genes in module
#35 and their overlap with the eight GWAS gene lists. Many
GWAS-hit genes were related to synaptic function, signal
transduction, and neuronal development and morphogenesis
(Table 2). Of specific interest, and consistent with current
hypotheses for the molecular pathology of MDD, was the inclusion
of brain-derived neurotrophic factor (BDNF) and other factors
implicated in development and maintenance of cell circuits
(Ephrin receptors EPHA3 and EPHA 5; Netrin G1 (NTNG1);
SLITRK3 and SLITRK5), of GABA-related genes (GABBR2,
GABRA4 and CALB1), glutamate receptors (GRM1 and GRM7)
and other signaling neuropeptides previously implicated in
mechanisms of psychiatric disorders [reelin (RLN) and gastrin-
releasing peptide (GRP)] (Table 2). Results from a pathway
enrichment analysis confirmed the role of genes in module #35 in
overall signaling mechanisms (Table 3). Together, these results
suggest that module #35 may include multiple components of
functionally-relevant local cell circuits.
Control Studies
To demonstrate the improvement of meta-clustering versus
single study clustering, we compared the histograms of p-values
obtained under those different conditions. In Figure 3, the
histogram of the minus log-transformed p-values of the Stouffer
statistic was first plotted for the 50 meta-modules obtained from
the case and control combined analysis. Module #35 with 88
genes is shown to have an aggregated minus log-transformed p-
value at 4.4 (i.e. p = 4e-05). We then applied the penalized K-
medoid method with the same parameter setting (K= 50 clusters
and 25% of scattered genes) for each single study. The 11 single
Figure 2. Consistent association of genes in module#35 with MDD-related gene categories. (a) Heatmap of log10-transformed p-values
from Fisher’s exact test for 50 modules obtained from MDD cases and matched controls and 8 MDD related GWAS and 3 negative controls. (b)
Heatmap of log10-transformed p-values from Fisher’s exact test for 50 modules obtained from controls and 8 MDD related GWAS and 3 negative
controls. The green rectangle identifies module #35.
doi:10.1371/journal.pone.0090980.g002
A BDNF/GABA/Glutamate Gene Meta-Module in Depression
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e90980
study histograms of Stouffer p-values showed overall much weaker
statistical significance than for module #35. Particularly, none of
the 550 modules from 11 single study cluster analysis was enriched
(p-value threshold 0.05) in more than three GWAS results
(Figure 3). Only four out of the 550 modules had more than
14 genes (,15% of the 88 genes; indicated by blue arrows in
Figure 3) that overlapped with module #35. Hence, the meta-
clustering approach efficiently combined weak signals in single
studies to identify a stable and biologically more meaningful gene
module. In other words, module #35 would not have been
discovered without combining 11 studies.
We next tested the meta-clustering approach using transcrip-
tomic data from control subjects only (i.e., removing all MDD
subjects) from the same 11 studies. Out of the 50 modules
generated, no module was enriched in more than two GWAS
studies (p-value threshold 0.05) among the eight GWAS results (see
Table S5 and heatmap in Figure 2 (b)), indicating that the
inclusion of the MDD cases was necessary for the detection of
significant module/GWAS overlap (i.e. module #35). We note
that this comparison is not a ‘‘proof’’ of the significance of module
#35 since the ‘‘control-only’’ analysis contains only half the
sample size of the ‘‘cases+controls’’. To investigate the impact of
the sample size, we randomly sampled half cases and half controls
to perform ‘‘cases+controls’’ versus ‘‘control-only’’ comparisons.
We meta-analyzed the p-values of the eight enrichment analyses
(using Stouffer’s method) in each module and retain the most
Table 2. Functional groups of 88 gene in module #35.
Functional groups Gene Symbols
Transmembrane cellular localization CLSTN2, SYT4, LRRC8B, GPR6, TMEM158
ST8SIA3, GABBR2, NRN1, ST6GALNAC5
GLT8D2, MPPE1, GNPTAB, PVRL3, SLC35B4
SLC35F3, KCNG3, SLC30A9, PTGER4, CYP46A1
GABRA4, UST, LOC646627, NTNG1, TMEM200A
TMEM70, RFTN1, GRM1, TMEM132D, KCNV1
EPHA3, CDH12, EPHA5, BEAN, SLITRK3
FREM3, GRM7, CD82, SLITRK5, VLDLR
Neuronal development and morphogenesis BDNF, SLITRK3, RPGRIP1L, MAEL, NTNG1,
RELN, LAMB1, SLITRK5, MYCBP2d
GABA and glutamate GRM1, GRM7, GABBR2, GABRA4
Cell adhesion PPFIA2, CDH12, FREM3, CLSTN2, PVRL3, RELN
LAMB1
Transcription regulation EGR3, DACH1, HDAC9, ATOH7, SLC30A9
ATF7IP2, ZNF436, MYCBP2
Annotations are based on Gene Ontology. See Table 3 for a separate analysis of pathway enrichment.
doi:10.1371/journal.pone.0090980.t002
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significant one (i.e. smallest p value) among the 50 modules. The
procedure was repeated for 20 times. The result shows that meta-
coexpression analysis using case and control samples combined has
better detection power to identify modules associated with
neuropsychiatric diseases. In Figure S2, the red cross shows
result of ‘‘control-only’’ and the histogram shows the 20
subsampled ‘‘cases+controls’’. The result from the full ‘‘cases+
controls’’ is also shown for reference (blue cross). We also tested
the meta-clustering approach using transcriptomic data from
MDD subjects only (i.e., removing all control subjects) from the
same 11 studies. Among the 50 modules generated, one module
(module #15 with 169 genes) was enriched in six out of the 8
GWAS categories (p,0.05) but notably not in the gene set
corresponding to the Mega GWAS MDD (p= 0.29) and to MDD-
related studies (p = 0.43) in the catalog of GWAS (Table S7). This
module only has 3 genes overlapped with the 88 genes (ST8SIA3,
GRM7 and MYCBP2) of module #35 extracted from the case
and control combined analysis. Pathway analysis of this module
indicated an over-representation of signal transduction pathways
(Table S8). Overall, the statistical significance of results using
MDD data only was lower and potentially inconclusive (i.e. at
background noise level).
Together these results indicate that combining MDD and
control subjects in meta-clustering approaches increased the
significance and robustness of the results, as demonstrated by
the identification of the tight module of 88 genes with high
relevance to current biological knowledge about MDD.
Discussion
Using methods we developed to identify meta-analyzed
coexpression modules across transcriptome datasets, we report
the identification of a module consisting of 88 genes that is
significantly enriched in genetic variants located nearby genes
otherwise associated with major depression and related pheno-
types. The finding of a significant intersection of two unbiased
large-scale approaches (transcriptome and GWAS) provide robust
evidence for the putative recruitment and contribution to
molecular and cellular mechanisms of MDD of a biological
module that is formed by the identified gene set. This module
includes numerous genes encoding proteins implicated in neuronal
signaling and structure, including glutamate metabotropic recep-
tors (GRM1, GRM7), GABA-related proteins (GABRA2, GA-
BRA4, CALB1), and neurotrophic and development-related
Figure 3. Histograms of the –log10(p) of the Stouffer statistic from 50 modules of meta-analysis of 11 MDD studies and each single
study.Module#35 with 88 genes (red arrow and double-cross) have largest –log10 transformed p-value of Stouffer’s statistic 4.4. The other four blue
arrows and double crosses indicated that these four modules in all single studies have more than 14 (15% of the 88 genes in module #35)
overlapped with module #35. See detailed description in text.
doi:10.1371/journal.pone.0090980.g003
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molecules [e.g., BDNF, reelin (RELN), Ephrin receptors (EPHA3,
EPHA5)]. These findings are consistent with current hypotheses of
molecular mechanisms of MDD, notably with the GABA,
glutamate and neurotrophic hypotheses of depression
[27,44,45,46,47]. This biological ‘‘internal validation’’, combined
with control studies showing that these results could not be
achieved using single studies (due to weak signal) demonstrates that
integrating transcriptome data, gene coexpression modules and
GWAS results can provide a novel and powerful framework to
improve understanding of MDD and other complex neuropsychi-
atric disorders. This approach also provided here a set of putative
interacting molecular partners, potentially reflecting a core
biological module that is recruited and implicated in biological
mechanisms of MDD.
The meta-clustering approach in this paper has the following
novelty and advantages. (1) Meta-analysis: Our result indicated that
a meta-analysis of gene clustering to combine multiple transcrip-
tome studies can identify more accurate and robust gene modules,
since the same clustering method applied to single studies did not
lead to the identification of any significant and/or neuropsychi-
atry-related module. (2) Cluster analysis allowing ‘‘scattered genes’’:
Gene coexpression modules were identified by penalized K-
medoid. This clustering technique searches for tight gene modules
and allows some genes to be scattered. This means that they are
not included in the final set of modules/clusters, unlike other
traditional clustering methods, such as hierarchical clustering, K-
means or self-organizing maps that force all genes into clusters. In
genomic applications, it was shown that allowing scattered genes
can improve clustering performance with better biological
knowledge discovery [34]. (3) Integration and validation with external
databases: Integration with rich GWAS and pathway knowledge
databases for biological and disease interpretation identified a
robust module with 88 genes that is consistent with current
knowledge about depression, hence providing some level of
‘‘internal control’’ for the methods. (4) Case and control combined co-
expression analysis: We showed that the combination of case and
control coexpression analysis was necessary to reveal the co-
expression perturbation originating from the disease. This is an
important observation as coexpression studies rely on subtle
differences in expression patterns compared to differential
expression between two groups. Hence disease-related coexpres-
sion modules could have been predicted to be unique to the
disease groups and ‘‘diluted’’ when combined with control data.
However, we show that the opposite is true, resulting in increased
power in the combined dataset. For technical validation, we have
performed the following: First, we fine-tuned the parameters to be
used in the final meta-clustering analysis (i.e. number of modules,
percentage of allowed scattered genes in penalized K-medoid
method) and tested those parameters in three studies using
‘‘surrogate’’ information, i.e. gene families and biological pathways
broadly associated with psychiatric disorders (See Methods).
Second, subsampling and bootstrap simulation were applied to
investigate the stability of the identified gene modules. Third, three
non-psychiatric related GWAS gene sets (cancer, human body
indexes and disease traits unrelated to mental functions) served as
negative controls.
Coexpression links between genes are inferred from microarray
expression studies but do not refer to any specific mechanism
underlying these correlations. In fact, any mechanism that
synchronously regulates transcription of multiple genes may
potentially generate coexpression relationships, including biophys-
ical sources (e.g., transcription factors, spatial configuration of
chromosomes, mRNA degradation, miRNA or other upstream
regulation, histone acetylation and methylation patterns), technical
effects (e.g., batch processing, RNA quality), cell biological sources
(e.g., cellular admixture of the sampled tissue, brain region), and
importantly synchronized activities across cells under homeostatic
equilibria corresponding to ‘‘control’’ states, trait conditions, or
chronic disease states for instance. Here, results in module #35
identify a set of genes whose products are distributed across cell
types, cellular compartments and biological processes (Tables 2–
3) that together contribute to various and potentially complemen-
tary biological processes, and whose collective function may be
related to pathological processes implicated in depression.
The biological content of the identified gene module is notable
in that it brings together multiple genes that have been otherwise
associated with depression and other neuropsychiatric disorders
through multiple studies both in humans and animal models, in
addition to the genetic links (i.e., GWAS) that were used here to
identify them. Such commonly associated genes include those
coding for BDNF, and GABA- and glutamate receptors, for
instance [18,19,20,21,22]. Prior findings often refer to differential
expression, e.g. reduced BDNF [22], or reduction in calbindin
(CALB1) positive GABA neurons [48]. Here, reports of conserved
co-regulated patterns between these genes suggests that changes in
the fine-tuning and synchronization of the function of these gene
products across cells and pathways may contribute to pathophys-
iological mechanisms related to brain dysfunction in MDD. The
fact that these results implicate genes that are likely to be expressed
across cell types or to regulate ensembles of cells (i.e. neurotrophic
and neuro-maintenance factors) is consistent with mechanisms
expected for polygenic complex disorders. Moreover, the identi-
fication of module #35 through overlap with GWAS findings for
traits (i.e. neuroticism) and other neuropsychiatric disorders
(Figure 2) also suggests that those genes may participate in basic
cellular functions that are implicated in a continuum of biological
states (i.e., from normal to disease brain functions), consistent with
a dimensional understanding of biological mechanisms of brain
disorders. The fact that borderline significance in gene overlap was
also observed for categories of disorders sharing clinical risk with
MDD (i.e. cardiovascular diseases, inflammation and metabolic
syndrome) suggest that the same gene sets may also contribute to
dysfunctions in peripheral organs through pleiotropic functions of
common genes, hence providing putative biological links for the
clinical and symptom co-morbidity. Follow-up studies of coex-
pression patterns obtained in datasets across these disorders may
be necessary to further investigate these interesting hints.
So while these studies provide insight into the biology of
complex disorders, one may reasonably ask how they may
contribute to the generation of novel hypotheses and predictions.
Two directions are worth mentioning. First, for the purpose of
therapeutic development and target identification, the application
of graph theory and other network analysis may help identify
critical genes within the identified module or upstream factors, as
potential mediators of the function of this module in disease state.
Preliminary analyses of the network properties of module #35 did
not provide clear insight into hub genes or other parameters of
interest (data not shown); however these studies may be
confounded by circular analyses within the same datasets. Thus,
testing these hypotheses in other large-scale disease related datasets
are needed to, firstly, refine gene membership into the identified
module, in view of the reasonable and significant conservation of
module structure across datasets, although not to absolute levels;
and, secondly, to identify key network nodes with conserved cross-
studies functions, as potential targets to modulate the functional
outcome of the identified gene module. Finally, an additional and
important outcome of these studies is that they provide a focused
set of genes, which can be used for follow-up genetic association
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studies, hence potentially mitigating the problem of reduced
statistical power of large scale genome-wide studies.
There are several limitations to this study. First, there is a bias
when selecting gene sets from the catalog of published GWAS
results since the targeted markers (SNPs) are updated every six
months, and many more SNPs were reported in the past five years
when GWAS have achieved greater sample size (including studies
with more than 10,000 participants) and detection of markers with
very small effect size. However, large sample sizes will also
introduce a bias towards false positive markers. A related
limitation is that the choice of markers (or gene) was based on
fixed and arbitrary thresholds (i.e., p-value and genomic distance).
Moreover, we used only a small fraction of the datasets and pre-
defined pathways related to psychiatric disease to decide on the
number of clusters and sets of scattered genes during the method
development phase, so the result of the clustering approaches may
still show some instability and may vary based on different
numbers of clusters and applied thresholds. Indeed, although we
performed extensive validation analyses to select the clustering
parameters and increase stability of modules, the 88 genes in
module #35 will inevitably vary slightly under additional data
perturbation (e.g., when adding additional MDD or related
studies). An additional limitation is that generating gene coex-
pression modules using cluster analyses is known to be sensitive to
small data perturbation. To mitigate these effects, we combined
multiple studies and concentrated on tight modules by leaving out
scattered genes. While this approach increased the power of the
meta-clustering method, it also meant combining datasets from
different brain regions, hence potentially diluting the effects of
local coregulation patterns that may be important for disease
mechanisms. The integration of multiple datasets comes at the
expense of variable technical platforms, including inclusion of
different probesets across array types. We investigated this
potential issue and showed considerable overlap in genomic
region targeted by the various probes for a same gene (Figure S3),
hence lowering the potential impact of this array differences. So
these results should be considered proof-of-concept, rather than
experimentally and biologically optimized. Finally, it is important
to note that changes in gene coexpression are difficult to confirm
by independent measures. Indeed coexpression links rely on large
sample size and we previously showed that the sample-to-sample
variability in array-based measures of expression is typically lower
than the variability obtained using alternate measures such as
quantitative PCR [24], so the ultimate test of the added value of
these meta-coexpression studies will need to come from additional
independent studies. Nonetheless, this study allowed the identifi-
cation of a focused set of genes for use in future genetic association
studies, and together demonstrates the importance of integrating
transcriptome data, gene coexpression modules and GWAS
results, paving the way for novel and complementary approaches
to investigate the molecular pathology of MDD and other complex
brain disorders.
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Figure S1 Diagram of pre-processing procedure of 11
MDD transcriptiome data sets. Number of samples and
number of matched genes in each single (MDD) study. In
matching step, we allowed 20% missing studies, then 16,443 genes
were identically matched among 11 studies. 13,500 genes were
kept by filtering out lower sum ranks of median row means; 10,000
genes were kept by filtering out lower sum ranks of median row
standard deviations.
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Figure S2 Histogram of minimum log10-transformed p
values from Stouffer’s statistics for 50 modules obtained
from randomly selected MDD cases and matched
controls into half for 20 times. Red cross represents the
minimum log10-transformed p value for controls only study and
blue cross represents the minimum log10-transformed p value for
cases plus controls study.
(TIFF)
Figure S3 Sequence target overlap between Affymetrix
and Illumina array probesets. We have systematically
mapped the respective probes that were chosen by our approach
and used genes in module #35 to specifically look at overlap in
targeted regions. As shown in the individual graphs below, there is
overlap in regions for 94% of the genes, indicating that for a few
exceptions the same transcript region is used. A histogram
represents a chromosomal area of a target sequence in either
affymetrix or illumina platform. Wider histogram means the target
sequence span over DNA sequence more widely. The height of
each histogram shows the number of studies use that specific
probe. See main text for additional information.
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